INTRODUCTION
Vaccines are some of the most effective tools for the prevention of infectious diseases (Halsey, 2003) . Despite the fact that currently licensed vaccines have been proven to be safe, safety issues have emerged that have resulted in some members of the public having a poor perception of vaccines. As vaccine usage increases and the incidence of vaccine-preventable diseases is reduced, vaccinerelated adverse events become more frequent and prominent (Offit et al., 2008; O'Hagan and Rappuoli, 2004; Mc Phillips and Marcuse, 2001) . The majority of vaccines currently in development consist of highly purified antigens or recombinant proteins, representing subunits of pathogens. The common strategy for the development of new-generation vaccines is to add well characterized adjuvants that only stimulates the component of the immune response essential for protection, and do not trigger a more generalized activation of the immune response (O'Hagan, 2001) . In spite of obvious benefits, decades of research and hundreds of pre-clinical candidates, and proven safety and efficacy, only a handful of adjuvants are currently approved for prophylactic vaccination of humans (Schijns and Lavelle, 2011) .
Adjuvants are included in vaccines for a variety of reasons. They may function to amplify the immune response, resulting in lower antigen doses that are required for a robust response to vaccination while increasing the breadth of response. Additionally, adjuvants allow for the formulation of complex combination vaccines thereby overcoming antigenic competition. Furthermore, adjuvants are extremely important in enhancing the limited immune response in some populations, such as the elderly, young children, chronic diseases and immunocompromised. They also function to increase effector T cell response and antibody titers, induce protective responses more rapidly, extend the duration of the response by enhancing memory B and T cell responses and facilitate increased vaccine stability (Schijns and Lavelle, 2011; O'Hagan and Gregorio, 2009) .
The development and eventual introduction of new adjuvant for vaccines is a challenging and daunting task for not only the vaccine manufacturers but also the regulatory authorities (Sesardic and Dobbelaer, 2004) . Adjuvants are not licensed alone without being incorporated into a vaccine because it is a part of the vaccine (Verdier, 2002) . Proper and thorough preclinical and toxicology studies need to be developed and designed to appropriately determine the safety profile of the adjuvant and the safety profile of the combination of the antigen and the adjuvant (Sesardic et al., 2007) . Safety and a lack of universality appear to be the major hurdles for the acceptance of new adjuvant. The European Medicines Agency (EMA) published a guidance that emphasizes a number of additional points: quality of manufacture of the adjuvant alone and in combination with vaccine antigens, nonclinical proof of concept and toxicity studies, and clinical development that assesses the adjuvant effect and dose required (EMA, 2005) . Since each combination of one or more antigens with an adjuvant has its unique safety and efficacy profile, they are licensed and regulated as individual vaccine products in combination Kenney and Cross, 2010) . Currently, there are only 5 licensed vaccine adjuvants for human use: Alum, MF59, Virosomes, AS03 and AS04. Safety has always been the main obstacle to the development of new vaccine adjuvants (O'Hagan and Gregorio, 2009; Vogel and Hem, 2008; Glenn and O'Hagan, 2007; Brennan and Dougan, 2005) . Thus, this manuscript aims to review the safety of licensed vaccine INTRODUCTION adjuvants and describe the proposed mechanism of action of those adjuvants.
METHODS
Potential publications for inclusion were identified through a direct search of PubMed/Medline database (http://www.ncbi.nlm.nih.gov/pubmed/). Other sources of information used included textbooks and internet searches (www). The following search terms were used: "adjuvant(s)", "vaccine adjuvant", "adjuvanted vaccines", "safety of vaccine", "safety of adjuvant", "licensed vaccine adjuvants", "alum adjuvant". All articles were reviewed to select relevant publications. Results of online literature searches were complemented by relevant papers cited in published studies along with the authors' knowledge of published studies.
RESULTS
There are several new adjuvants in preclinical and clinical development. Some new adjuvants have recently been licensed for human use in the EU. Alum has represented the only adjuvant licensed in US until 2010 when the HPV vaccine containing AS04 adjuvant was licensed (table 1) . This review will only focus on the licensed vaccine adjuvants.
Aluminum salts

Mechanism of action
Three probable mechanisms have often been cited to explain how aluminum-containing adjuvants increase antibody production; the inflammation mechanism; the depot mechanism, and the promotion of uptake of antigens by APCs (Gupta et al., 1995) . Recent work proposed that particulate adjuvant is not simply antigen delivery systems but can also act as immunopotentiators (Edelman, 2002) . Alum has been shown to activate human monocytes and macrophages in vitro (Rimaniol et al., 2004; Ulanova et al. 2001; Seubert et al., 2008) and synergize with TLR-dependent adjuvants resulting in the secretion of IL-1β by human peripheral blood mononuclear cells (PBMCs) as a result of the activation of the inflammasome complex (Li et al., 2007) . Injection of Alum induced the enrollment of inflammatory monocytes that were able to move into lymph nodes, and the formation of uric acid, which stimulates the immune system through the NLRP3 inflammasome complex (Kool et al., 2008) . As already described, NLRP3 has been implicated in Alum adjuvanticity (Eisenbarth et al., 2008) . However, the direct mechanism of action has yet to be determined.
Alum does not effectively induce mucosal IgA antibody responses. In addition, Aluminum salts primarily stimulate a Th2 response, which results to the induction of IgE antibody production, and possibly associated with allergic reactions in some subjects (Gupta, 1998; Relyveld et al., 1998) . The dose of aluminum adjuvant is an essential consideration. It is important to understand that there may be an optimal level of aluminum for a given vaccine antigen, with immune responses decreasing at increased levels of aluminum. Nevertheless, aluminum has been found to remain at the site of injection for a long period (Gupta, 1998) . Small particles of aluminum salts can be internalized by dendritic cells (Morefield et al., 2005) and are known to be removed from the body over time (Hem, 2002) . The acceptable dose of aluminum in adjuvants ranges up to 1.25 mg both by US and by WHO regulations, but currently licensed US vaccines have a range of only 0.125 -0.85 mg (Baylor et al., 2002) .
Safety
Alum has been the usual first choice for many vaccines due to its long history of use and known safety profile (Alving, 2009 ). Alum-adsorbed vaccines induce local reactions (for example redness, pain, and hardening of the injection site) in a significant number of recipients, but these adverse reactions are frequently light to moderate and of short duration. Systemic reactions can infrequently happen, including malaise, fever and aches (O'Hagan and Rappuoli, 2004) . Focal histologic lesions linked to alumcontaining vaccines, which is known as Macrophagic Myofasciitis (MMF), were first reported in France in 1998. Five years later, more than 200 definite cases have been identified, and isolated cases have been documented in other countries (Gherardi, 2003) . A retrospective analysis of 18 cases seen in five myopathology centers was done between May 1993 and December 1997. Polymyositis (inflammatory muscular disease) and polymyalgia rheumatica (sometimes referred to as PMR) were the leading presumptive diagnoses. Twelve patients reported myalgia, nine reported arthralgia, six reported muscle weakness, five reported pronounced asthenia, and four reported fever. Abnormal laboratory findings were infrequently observed which included increased creatine kinase, increased erythrocyte sedimentation rate and myopathic electromyography (Gherardi et al., 1998) .
Muscle biopsy findings included focal infiltration of epimysium, perimysium and perifascicular endomysium 
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by sheets of large basophilic cells of the monocyte and macrophage lineage (CD68 + , CD1a -, S100 -). These cell infiltrates express major histocompatibility complex (MHC) class 1 and MHC class 2 antigens, with a finely granular periodic acid-Shiff (PAS)+ content appearing as small osmiophilic spiculated structures on electron microscopy. Additional lymphocytic infiltrates intermixed with macrophages and formed micro vascular cuffs of CD8 T cells or lymphoid follicles with an observed lack of significant muscle fiber injury. Microorganisms were not detected using typical staining (Ziehl-Neelsen, auramine, Gram) or via electron microscopy. The myopathologic pattern was different from idiopathic and sarcoid-like inflammatory myopathies and from fasciitis-panniculitis syndromes (Gherardi & Authier, 2003; Naschitz et al., 1996) . Patients had normal results on both renal function tests and aluminum plasma levels, which lead the investigators to consider the likelihood of a focal accumulation of aluminum unrelated to passive deposition from the blood. Macrophage infiltrates were not observed elsewhere than in muscle in adult patients (Gherardi et al., 1998) , and in fact the MMF lesion was detected completely in the deltoid muscle (Gherardi et al., 2001) . Because aluminium salts are used as an adjuvant in several vaccines administered intramuscularly into deltoid and quadriceps muscles, it has been postulated that MMF may represent a rare and unusual reaction to intramuscular injections of aluminium-containing vaccines (Gherardi and Authier, 2003) .
The Vaccine Safety Advisory Committee (VSAC) of the World Health Organization (WHO) reviewed MMF in 1999. The VSAC concluded that there was no basis for recommending a change in vaccination practices involving vaccine selection, schedule, delivery practices, or information involving aluminum-containing vaccines. The VSAC also recommended further research to assess the clinical, epidemiological and basic science aspects of MMF (WHO, 1999) . The US Food and Drug Administration (US FDA) also validated the safety of aluminum salts in vaccines (Baylor et al., 2002) .
Studies have demonstrated that at all time points after vaccination, the calculated body burden of aluminum remains less than the minimal risk level (Keith, 2002) . Thorough evaluation of hundreds of thousands of doses of whole-cell and acellular pertussis vaccines and hepatitis B vaccines (most of which contained aluminum adjuvants) derived from large population trials and cohort studies has shown no evidence of serious or longterm effects Demicheli et al., 2003) . A meta-analysis of the available safety data on alum from 35 reports of studies found no evidence of serious or longterm adverse effects (Jefferson et al., 2004) .
MF 59
Mechanism of action MF59 was the 1 st adjuvant to be approved for human use after aluminum salts. Despite limitations and numerous endeavors over the years to identify alternative adjuvants, aluminum salts continued to be the only vaccine adjuvant acceptable for human use until the late 1990s. The first alternative adjuvant to gain acceptance since aluminum salts was MF59 emulsion, which gained approval for human use first in Italy in 1997, then in 23 countries (including 12 in EU) for use as a part of the influenza vaccine for elderly subjects. MF59 was discovered, developed and is currently produced by Novartis Vaccines (now part of GSK vaccines). The long period between the introduction of aluminum salts and that of MF59 was mainly due to the safety profile required of adjuvants to gain approval for use in humans. Unlike several earlier candidates, MF59 met all the required criteria for safety (Podda et al., 2005; Sahly, 2010; Pellegrini et al., 2009) . MF59 was originally developed as a vehicle for a muramyl peptide adjuvant, MTP-PE, but was found to possess distinct adjuvant properties. The current version of the MF59 emulsion is a second-generation formulation with the addition of citrate for better stability (Podda et al., 2005) .
MF59 has been demonstrated to be an effective adjuvant in a varied range of species in combination with an extensive range of vaccine antigens, including recombinant proteins, isolated viral membrane antigens, bacterial toxoids, protein polysaccharide conjugates, peptides, and virus-like particles. MF59 is particularly effective at inducing high levels of antibodies, including functional titers (neutralizing, bactericidal and opsonophagocytic titers) and is commonly more potent than aluminum salt adjuvants (figure 1). The level of immunogenecity achieved over aluminum salts is adaptable and is determined by the antigen and species under evaluation (Podda et al., 2005; Singh et al., 2006) . In spite of known efficacy, the mechanism of action of MF59 is not completely understood. Initial reports attributed the mechanism of action to a depot effect; providing the antigen in an oil-in-water emulsion that results in a slow release of the antigen (Herbert, 1966) . Nonetheless, the depot effect of the MF59 adjuvant was later disputed after a study showed that soluble gD2 antigen from herpes simplex virus (HSV) and MF59 injected intramuscularly in mice had varying clearance kinetics and the presence of MF59 did not modify the clearance kinetics of the antigen (Dupuis et al., 2000) . Using a comparable model, Dupuis et al. found out that MF59 was internalized by dendritic cells (DCs) and facilitated the internalization of the gD2 antigen, therefore developing the possibility that a direct interaction with and activation of dendritic cells are more probable explanations of the adjuvant effect (Dupuis et al., 1998) .
Safety
Literature on the safety of MF59 in humans can be divided into two categories: data from clinical trials and data from post-marketing safety surveillance. Clinical trials using numerous MF59-adjuvanted vaccines have been completed in different age groups (elderly, younger adults, adolescents, newborn infants), and demonstrate increased immunogenicity of co-administered antigens with a high level of safety and tolerability (Podda et al., 2005; O'Hagan et al., 2011) . For the most part, clinical experience and safety data of MF59 safety have been collected in conjunction with influenza vaccines that have followed over 14,000 individuals vaccinated in more than 30 clinical studies (Podda et al., 2005; Frey et al., 2003; Banzhoff et al., 2003; Gasparini et al., 2001; Podda, 2001; De Donato, et al., 1999; Minutello et al., 1999; Martin, 1997) . For instance, Fluad® had been studied in 28 single-or double-blind, randomized and controlled studies, 13 of which with a 4-to 6-month follow-up and 12 studies with a 4-week follow-up before it was granted approval in May 1997. Twenty-four of 30 studies included elderly subjects (≥65 years). Fluad® was tested for equivalence of antigenic content against the inactivated subunit comparator vaccine Agrippal® (same antigenic content but without MF59), in twenty, against Fluogen®/Fluvirin® in one study, against Fluzone® in two studies, against Influvac® in three studies, and against Flushield® in two studies (Schultze et al., 2008) .
Moreover, MF59 has been studied in clinical trials with herpes simplex virus (HSV), human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C virus (HCV), E. coli, parvovirus, and human papilloma virus (HPV) vaccine candidates. MF59 has also been tested in various formulations, including single-container presentation (HSV vaccine, influenza vaccine), dual container without buffer in the MF59 portion (influenza vaccine), and dual container with citrate buffer in the MF59 portion (HBV vaccine, influenza vaccine), like the current vaccine formulation (Schultze et al., 2008) .
There are two integrated analyses of safety data from MF59-adjuvanted influenza vaccine clinical trials. A meta-analysis published in 2001 assessed the safety data from 20 clinical trials that were performed as part of the Fluad® registration package submitted for evaluation to the European Medicines Agency (EMA) (Podda, 2001 ). Five of 20 trials evaluated the safety of the vaccine given annually in the second influenza season, while 2 of the trials evaluated the vaccine in the third ensuing influenza seasons. All study subjects were elderly (≥65 years of age) and received 1 dose of MF59-adjuvanted seasonal influenza vaccine or non-adjuvanted seasonal influenza vaccine (Podda, 2001) .
In 2009, a more recent analysis encompassing the aforementioned 20 trials and an additional 44 other trials were published . The trials were heterogeneously designed in terms of age group (infant to elderly), study design (controlled and uncontrolled), duration of observation (3 weeks to >12 months) and the antigen used (pandemic or interpandemic influenza). The study supported the good safety profile of seasonal and pandemic influenza vaccines with MF59 and demonstrated benefit over influenza vaccines without MF59. An observational cohort study with a 3-month follow-up of neonates was done in 4,508 pregnant women (2295 vaccinated versus 2213 unvaccinated) to assess the safety of a MF-59 adjuvanted A/H1N1 vaccine (Focetria®). No maternal deaths or abortions were recorded among the vaccinated women. In addition, there were no differences between the vaccinated and unvaccinated cohorts observed for gestational diabetes, pre-eclampsia, stillbirth, low birth weight, neonatal deaths or congenital malformation after vaccination in all trimesters. The risk of premature birth was significantly lower among the women who got Focetria® (adjusted proportional hazard: 0.69; 95% CI: 0.51-0.92). (Heikkinen et al., 2012) . In 2009, a study assessed the safety and immunogenicity following a second year seasonal vaccination with Fluad® in children. With 89 subjects enrolled, it was demonstrated that the use of MF59-adjuvanted influenza vaccine was safe and highly immunogenic in young children (Vesikari et al., 2009) .
The positive safety profile of MF59-adjuvanted vaccines, as shown in clinical trials, are also supported by post-marketing pharmacovigilance. A review of the postmarketing surveillance data of Fluad® or Fluad®-like vaccines from September 1997 to August 2006 reported 1,400 single adverse events during a 9-year period whereby millions of doses of adjuvanted vaccines were administered (Schultze et al., 2008) . To ensure coherence and consistency of reported events, all were classified according to MedDRA. There were 13 cases of deaths reported, largely due to cardiovascular causes in older patients 68-91 years of age. None of these cases was attributed to the vaccine. Thirty-nine allergic reactions were reported, 7 were serious and none was fatal. There were 8 cases of encephalitis/myelitis reported, 2 of which were considered related to the vaccine. Nine cases of Guillain-Barré syndrome were recorded, reflecting an incidence of 0.03 cases per 100,000 recipients. This is lower than the annual incidence of Guillain-Barré syndrome in the general population (estimated to be at 0.6-4 cases per 100,000 persons). Three cases of Parsonage-Turner syndrome (acute brachial neuropathy and acute brachial radiculitis), 4 cases of thrombocytopenia, 1 case of leukocytosis, 3 cases of vasculitis and 1 case of purpura/microhematuria were reported (Schultze et al., 2008) . Banzhoff et al. reported spontaneous adverse drug reactions (ADR) from an estimated 12 million administered doses of the pandemic MF59-adjuvanted H1N1v vaccine (Focetria®) from the mass vaccination programs in Europe. A total of 5,315 pandemic vaccine ADR reports were received, of which 19.9% were serious. An rise in the reporting rate was observed after the use H1N1 pandemic vaccines (44.3 cases/100,000 doses). Rates of adverse events of special interest, for instance, Guillain-Barre syndrome, anaphylaxis, and convulsion, were similar between the pandemic and the seasonal vaccines. Thirtysix deaths were recorded after use of the pandemic vaccine, but none of them showed evidence for a causal relationship to the vaccine (Banzhoff et al., 2011) . Additionally, the MF59-adjuvanted pandemic vaccine did not demonstrate any association with narcolepsy, unlike the pandemic vaccine from GSK with the AS03 adjuvant .
AS03
Mechanism of action GlaxoSmithKline Biologicals (GSK; Rixensart, Belgium) has developed novel adjuvant combinations, called Adjuvant Systems. One such adjuvant system is AS03, an oil-in-water emulsion developed as an alternative to the water-in-oil emulsions, known to be potent immunostimulants but have been known to be too reactive for human use. The presence of α-tocopherol differentiates AS03 from other oil-in-water emulsion-based adjuvants (Garcon et al., 2012) . α-tocopherol is 1 of the eight isoforms of vitamin E and the most widely distributed in nature (Brigelius-Flohe and Traber, 1999) . It is also the form that better absorbed in the human body and found in various tissues including muscle fibers, adipose tissue, adrenal glands, pituitary glands, and the pancreas (Burton et al., 1998) . AS03 needs co-localization with antigen at the injection site. It stimulates short-lived expression of the transcription factor NF-κB, cytokine and chemokine responses and an amplified recruitment of innate immune cells to the site of injection. Monocytes are the major cell type that is activated to convert to antigen-presenting cells (APCs) and migrate to draining lymph nodes once loaded with antigen. The APCs then trigger naive CD4+ T cells, which interact and stimulate antigen-specific B cells (i.e. memory B cells and antibody-secreting plasma cells) (Garcon et al., 2012) .
Safety
The safety of the AS03-adjuvanted H5N1 vaccine has been evaluated in over 10,000 adults across different populations. In Phase III studies involving 5,071 (Rumke et al., 2008) and 4,561 subjects (Langley et al., 2011) , solicited local and general symptoms were more common in the AS03-adjuvanted vaccine groups than in the control groups (seasonal influenza vaccine and PBS, respectively), but symptoms were not serious and low grade in general. In adults (aged 18−60 years) from the first study (Hem et al., 2006) , 88% of subjects who received the first dose of the AS03-adjuvanted vaccine reported pain versus 64% of those who received the non-adjuvanted vaccine; 35−41% of subjects who received the first dose of AS03-adjuvanted vaccine reported fatigue, headache and myalgia versus 21−25% of those who received the non-adjuvanted vaccine. The occurrence and seriousness of recorded adverse events were in general lower with the second dose (Rumke et al., 2008) and in older versus younger adults (Garcon et al., 2012; Rumke et al., 2008; Langley et al., 2011) . Over 90 million doses of AS03-adjuvanted H1N1 vaccine were administered globally in >47 countries during the 2009-2010 H1N1 pandemic including some 9.6 million children and 1.5 million pregnant women. Active safety surveillance performed by national regulatory authorities during the pandemic season showed a clinically acceptable benefit-risk profile for the AS03-adjuvanted H1N1 vaccines (Garcon et al., 2012) .
Cases of narcolepsy, especially in children and adolescents, following widespread use of vaccines against influenza ( A retrospective cohort study in Finland demonstrated an abrupt increase in the incidence of childhood narcolepsy associated with AS03-adjuvanted AH1N1 vaccine (incidence of narcolepsy was 9.0/100,000 in the vaccinated versus 0.7/100,000 person-years in the unvaccinated children and adolescents). The result translates to a rate ratio of 12.7 (95% CI 6.1-30.8). In vaccinated 4 to 19-year-olds, the vaccine-attributable risk of developing narcolepsy was 1:16,000 (95% CI: 13,000-1:21,000). This observation was supported by studies from Sweden. Conversely, both Canada and the United Kingdom did not report any increase in the frequency of narcolepsy after administration of Pandemrix even though genetic susceptibility to narcolepsy is as common in these countries as in the Nordics. This suggests a multifactorial nature of narcolepsy (Nohynek et al., 2012) .
The Swedish Medical Products Agency issued a preliminary report on 28 March 2011 following an investigation on pandemic influenza vaccination from regional vaccination registries of 4 Swedish counties. The risk of narcolepsy was compared in vaccinated and unvaccinated individuals from October 2009 to December 2010. The Agency reported the relative risk (RR) of narcolepsy was 4x higher in vaccinated children and adolescents (born from 1990) compared to unvaccinated children and adolescents. The RR translates into an absolute risk of about 3 cases of narcolepsy in 100,000 vaccinated adolescents/children. The incidence rates for narcolepsy in adults, whether vaccinated or unvaccinated, were similar to historical national registry-based rates during the years before the pandemic period (about 1/100,000) (Swedish Medical Products Agency, 2011). The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) reviewed all available data, including new findings from Sweden and France. Similar to earlier results of the Finnish epidemiological study, the CHMP concluded that the new evidence, although having limitations in the methodology of the data, supported the signal in children and adolescents (WHO, 2011) . Figure 2 shows the hypothetical model of autoimmunity in narcolepsy. Further studies are necessary to determine whether the association between adjuvanted pandemic vaccinations and narcolepsy can be demonstrated in other populations. Further research on the underlying immunological mechanism is also warranted.
ASO4
Mechanism of action AS04 is a combination of 50 µg of the immunostimulator MPL (3-O-desacyl-4'-monophosphoryl lipid A) and 500 µg of aluminum salt. MPL is a detoxified form of the lipopolysaccharide extracted from the Gram-negative bacterium Salmonella, Minnesota strain R595. MPL includes an immune stimulatory activity similar in quality to lipopolysaccharide, albeit lower in magnitude. This was discovered to be due to the ability of MPL to act as a Tolllike receptor 4 (TLR4) agonist (Garcon, 2010; Qureshi et al., 1982; Casella and Mitchell, 2008; Didierlaurent et al., 2009) . Two AS04-adjuvanted vaccines are licensed for human use: (1) the human papillomavirus 16/18 (HPV-16/18) vaccine, Cervarix® (GlaxoSmithKline) and (2) FENDrix® (GlaxoSmithKline), a hepatitis B virus (HBV) vaccine for patients undergoing dialysis (Descamps et al., 2009) . At present, the AS04-adjuvanted HPV-16/18 vaccine has been approved in over 110 countries while the AS04-adjuvanted HBV vaccine has been approved in over 30 countries including the 27 countries of the European Union (Beran, 2008) .
AS04 stimulates localized and transient transcriptional activity of the transcription factor NF-ĸB, a key regulator of the innate response (Vallabhapurapu and Karin, 2009 ). AS04 stimulates transient production of cytokines at the site of injection. By 24 hours (Didierlaurent et al., 2009), AS04 directly triggers dendritic cells and monocytes to take up antigen and move towards the draining lymph nodes. The activated antigen-presenting cells (APCs) function to present antigen to and activate T cells. The fast and transitory stimulation initiated by AS04 allows the APCs to process and present antigens while the vaccine antigen concentration is elevated -this results in a more robust immune response (Garcon, 2010) .
Safety
Pooled analysis of the safety of the HPV-16/18 AS04-adjuvanted cervical cancer vaccine was concluded in a cohort of nearly 30,000 girls and women aged ≥10 years, who received at least 1 dose of the HPV-16/18 vaccine and 13,811 who received 1 of 3 controls [Al(OH)3 or hepatitis A vaccine]. Serious adverse events (SAEs), pregnancies, medically significant conditions (MSCs) and new onset of chronic diseases (NOCDs), including new onset of autoimmune diseases (NOADs), were monitored. Data were analyzed by vaccine group according to age (10-14, 15-25 and >25 years) and reporting period (months 0-7, months 7-12 and >month 12). Although rates of solicited local and general symptoms were higher in the HPV-16/18 vaccine group, there were no clinically relevant differences seen between the HPV-16/18 vaccine and pooled control groups in rates of SAEs (2.8% versus 3.1%), MSCs (19.4% versus 21.4%), NOCDs (1.7% in both groups) or NOADs (0.4% versus 0.3%), and no differences in pregnancy outcomes or rates of withdrawals due to AEs or SAEs were observed between the HPV-16/18 vaccine group and the control group. Results from the analysis of this large database confirm the favorable safety profile of the HPV-16/18 AS04-adjuvanted cervical cancer vaccine (Descamps et al., 2009) .
When comparing the AS04-adjuvanted HPV 16/18 vaccine with the quadrivalent HPV vaccine from Merck (Gardasil®), which is adjuvanted with aluminium hydroxide, the proportion of women reporting at least 1 solicited local or general adverse event within 7 days of any dose was 95% in the bivalent HPV vaccine group and 85% in the quadrivalent HPV vaccine group. The most common solicited local symptom in both groups was injection-site pain (93% vs 72%), and this was of grade 3 severity in 17% for the bivalent vaccine vs 3% for the quadrivalent vaccine. The local reaction associated with the AS04-adjuvanted HPV 16/18 vaccine is most probably related to the use AS04. The incidence of fatigue and myalgia was 50% and 28% with the bivalent HPV vaccine compared with 40% and 20% with the quadrivalent HPV vaccine. Adverse events were reported more frequently after the first dose than after subsequent doses in both vaccines. Rates of medically significant conditions were 30% and 27%, respectively. SAEs were reported in 6 versus 7 women, respectively, and new-onset chronic disease in 14 and 13 women (McKeage and Romanowski, 2011; Einstein et al., 2009) .
The clinical experience with the AS04-adjuvanted HBV vaccine among patients with renal insufficiency (including pre-hemodialysis and hemodialysis patients) has demonstrated a favorable safety profile similar to the standard HBV vaccines and has stimulated earlier antibody response and increased antibody titres as compared with 4 double doses of the standard HBV vaccine (Garcon, 2010; Beran, 2008) .
The single largest immunization program occurred in the United Kingdom (UK), where AS04-adjuvanted HPV-16/18 vaccine (Cervarix®) was the vaccine of choice for mass vaccination of adolescent girls. In a review of safety in the UK following the administration of at least 4 million doses since the start of routine immunization program (September 2008), the Medicines and Healthcare products Regulatory Agency (MHRA, 2010) and Commission on Human Medicines (UK Commission on Human Medicine, 2010) came into conclusion that the benefits of the vaccine continue to outweigh the risks. Similarly, the global monitoring of the available safety data for the AS04-adjuvanted HPV-16/18 vaccine validates its favorable safety profile following the distribution of at least 14 million doses worldwide (Garcon, 2010) .
Virosomes Mechanism of action
Virosomes are vaccine platforms that attempts to imitate the structure of a virus. Virosomes are virus-like particles, consisting of reconstituted viral envelopes, lacking the viral genetic material. They are also referred to as Immunopotentiating Reconstituted Influenza Virosomes (IRIV). They are 150 nm unilamellar vesicular proteoliposomes comprised of influenza H1N1 surface glycoproteins inserted in a mixture of natural and synthetic phospholipids. Virosomes can be generated from different enveloped viruses and are similar to the original virus in terms of morphology and cell entry characteristics. Reconstituted influenza virosomes preserve the receptor-binding and membrane fusion activity of the viral hemagglutinin (HA). Because virosomes do not have the viral RNA, binding and fusion to cells does not result in infection (Wilschut, 2009; Huckriede et al., 2005) . Virosomes have been used to enhance the immune response to vaccines against hepatitis A (Epaxal®, Berna Biotech) and influenza (Inflexal® V, Berna Biotech (now Crucell) and Invivac, Solvay Pharmaceuticals) (Cusi, 2006) .
Clinical studies have shown that intramuscular administration of virosomal influenza vaccines induce hemagglutination-inhibition (HI) titres similar to those stimulated by conventional whole virus or subunit vaccines. Inflexal® V has been proven to have an acceptable immunogenicity and safety profile in healthy adults, elderly and children (Herzog et al., 2002) . Inflexal® V is available under in Italy (Isiflu® V), Germany (InfectoVac® Flu), and the United Kingdom (Viroflu®) (Herzog et al., 2009) .
Virosomes are non-toxic, biodegradable, and do not induce antibodies against themselves (Cryz et al., 1996) . Virosomes are expected to allow antigen presentation in the context of both MHC I and MHC resulting in both Band T-cell responses (Herzog et al., 2009; Moser et al., 2007; Arkema et al., 2000) . Because of their capacity to induce cytokines such as GM-GSF, TNF-α, IFN-γ and IL-2 in PBMCs and to allow antigen depot, virosomes are capable of improving the immunogenicity of a variety of antigens (Cusi, 2006; Moser et al., 2007) . Virosomes interact directly with cells of the immune system, particularly Blymphocytes and dendritic cells. Membrane-associated immunoglobulin receptor molecules on B cells can identify hemagglutinin and neuraminidase spikes projecting from the virosomal membrane, including foreign antigens that may be linked to the surface of the virosomes. The arrangement of the antigens on the virosomal surface is presumed to allow crosslinking of these immunoglobulin receptors on B cells, leading to an exceptionally robust signal and consequent activation (Huckriede et al., 2005; Almeida et al., 1975) .
Safety
Safety and immunogenicity of Inflexal® V was shown through a randomized trial involving 126 elderly nursing home residents aged 63-102 (Gluck et al., 1994) . Another controlled study where 76 elderly subjects were enrolled demonstrated the very good immunogenicity of Inflexal® V for 2 of the three vaccine strains (Conne et al., 1997) . The best response to the vaccine was shown in subjects who had non-protective antibody levels at baseline. A randomized, multi-center study of 533 elderly subjects showed that Inflexal® V has a better trend than an MF59 adjuvanted vaccine in terms of pain, systemic reactions and additional medication to treat vaccine-related AEs (Zamparo and Little, 2011) . Comparable results were found in a controlled study involving 840 subjects aged 60 years or older (Ruf et al., 2004) .
Inflexal® V produced fewer local adverse events, especially where pain and tenderness were concerned (37%), in contrast to the comparator vaccine (51%) (Herzog et al., 2002) . Furthermore, a study in HIVinfected children (n = 23, mean age = 7.2 years) showed Inflexal® V to be well-tolerated with no influenza-like illness during 3 months follow-up. Furthermore, no significant changes were observed in the CD4+ count and the viral load. (Herzog et al., 2002; Zuccotti et al., 2002) .
A post-marketing study done with 405 children ranging in age from ≥6 months to ≤6 years found Inflexal® V to be safe, well tolerated and well accepted by parents (Kunzi et al., 2009) . Berna Biotech Ltd (now part of Crucell, a subsidiary of Johnson & Johnson) introduced an influenza virosomal vaccine for intranasal administration (Kunzi et al., 2009) and found that induction of protective immune responses via this route required coadministration of a strong mucosal adjuvant plus 2 consecutive immunizations. This vaccine formulation containing native, non-detoxified, E. coli heat-labile enterotoxin (LT) as mucosal adjuvant, was given marketing approval by Swissmedic in 2001 under the tradename NasalFlu®. The vaccine had to be withdrawn soon after introduction due to an increased number of cases of Bell's palsy associated with NasalFlu® (Mutsch et al., 2004) .
A study was performed to compare the immunogenicity and adverse effects of an inactivated hepatitis A vaccine based on virosomes (IRIV-HAV) Epaxal® and a standard vaccine using aluminum as an adjuvant (Al-HAV). Geometric mean antibody titers recorded at days 0, 14 and at 12 months were comparable in the two groups (IRIV-HAV and Al-HAV); however, the antibody concentrations recorded with IRIV-HAV at day 28 were lesser (p<0.0001) and at month 13 (p=0.02). The time to detect protective antibody levels in the blood was similar (Day 28: 98%, 12 months: 94%, 13 months: 100%). Local adverse effects were 17% (IRIV-HAV) and 66% (Al-HAV) (P<0.0001) after the 1 st vaccination and 32% and 42% respectively following booster (P=0.05). IRIV-HAV provided similar protection but caused fewer local adverse effects (Holzer et al., 1996) .
DISCUSSION
One of the most important aspects of adjuvant development is safety. Many experimental adjuvants have advanced to clinical trials and some have demonstrated high potency, but most have proven too reactogenic for routine clinical use. Adjuvant safety is critical and can retard, or stop development of an adjuvanted vaccine. The advantages of adding adjuvants into vaccine formulations to improve immunogenicity must be evaluated against the risk that these agents will cause adverse reactions. These adverse reactions often are brought about by the interaction of the adjuvant and the antigen itself, or perhaps because of the specific type of response to a certain antigen the adjuvant generates. Various abnormalities/diseases have been claimed to be linked with the use of adjuvants, for instances, autoimmune diseases, collagen diseases, or even cancer. Extensive epidemiological studies have, however, failed to show an association between adjuvanted vaccines and these theoretical risks. The type of adjuvant will strongly influence the development of antigen-specific T-helper (Th) cell populations, and cell-mediated or antibody profiles (table 2) .
Aluminum salts are the reference adjuvants for human vaccines. Various aluminum compounds are used, and aluminum hydroxide is the most widely used. The major mechanisms responsible for the adsorption of alumantigens are electrostatic attraction, hydrophobic forces, and ligand exchange. Alum-containing vaccines have a long experience with hundreds of millions of doses in human vaccines, showing the excellent safety profile: lack of parenteral side effects and relatively benign local side effects at the site of injection. This explains why this class of adjuvants has been a frequent first choice for many vaccines. Alum-containing vaccines can induce local reactions (e.g. redness, pain and hardening of the injection site) in a significant number of recipients, but these are usually mild to moderate and of short duration. Alumcontaining vaccines had been linked to focal histologic lesions which are called macrophagic myofasciitis (MMF). It was first reported in 1998 in France. Five years later, over 200 definite cases had been identified and isolated cases had been recorded in other countries. From an epidemiological perspective, MMF had particularly been observed in France. The increase in the number of cases diagnosed in France in the last few years might be a result of a modification of vaccine administration from the subcutaneous to the intramuscular route, or the use of the hepatitis B vaccine to a naive adult population expected to respond with a more robust local inflammatory response than to booster immunizations. The Vaccine Safety Advisory Committee of the World Health Organization (WHO) reviewed MMF at a meeting of the committee in 1999. The committee found that there was no basis for recommending a change in vaccination practices involving vaccine selection, schedule, delivery practices, or information involving aluminum-containing vaccines. The United States Food and Drug Administration (FDA) also confirmed its support of aluminum salts in vaccines. Alum-containing vaccines are safe.
MF59 was the 1 st adjuvant to be approved for human use after aluminum salts. The long period that elapsed between the introduction of aluminum salts and that of MF59 was primarily due to the safety profile that adjuvants must show to gain acceptance for licensure in humans. Unlike many previous candidates, MF59 met all the required criteria for safety. Clinical trials with several MF59-adjuvanted vaccines have been also performed in different age groups (the elderly, younger adults, adolescents, and also newborn infants). There is an integrated analysis from a large safety database, with more than 60 clinical trials and involved 20,447 subjects who received MF59-adjuvanted vaccines. The favorable safety data of MF59-adjuvanted vaccines demonstrated in clinical trials are supported by post-marketing pharmacovigilance. PMS (post-marketing surveillance) during a 9-year period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) in which millions of doses of adjuvanted vaccines were administered reported the excellent safety profile of MF59-adjuvanted vaccines.
AS03 is an oil-in-water emulsion adjuvant developed by GSK. It has gained importance in recent years for its use in H1N1 pandemic and H5N1 pre-pandemic influenza vaccines. AS03 contains a surfactant polysorbate 80 and two biodegradable oils, squalene and DL-α-tocopherol, one of the eight isoforms of vitamin E, in phosphate-buffered saline (PBS) as the aqueous carrier. The presence of synthetic a-tocopherol as an immunostimulant distinguishes AS03 from MF59, other oilin-water emulsion-based licensed adjuvant. The AS03-adjuvanted vaccines were well tolerated with an accepta- AS04 combines 50 µg of the immunoenhancer MPL (3-O-desacyl-4'-monophosphoryl lipid A) with 500 µg of aluminium salt. MPL is a detoxified form of the lipopolysaccharide extracted from the Gram-negative bacterium Salmonella minnesota strain R595. Two AS04-adjuvanted vaccines are licensed for human use: the human papillomavirus 16/18 vaccine, Cervarix® (GlaxoSmithKline) and FENDrix® (GlaxoSmithKline), a hepatitis B virus (HBV) vaccine for hemodialised patients. AS04 represents the first adjuvant licensed for human use in the USA after aluminium salts. A pooled analysis of the safety of the (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine was performed in a cohort of almost 30,000 girls and women aged ≥10 years. Analysis of this large database showed that Cervarix® has a favorable safety profile in women of all ages. Another result from a head-to-head study comparing the AS04-adjuvanted HPV 16/18 vaccine with the quadrivalent HPV vaccine which is adjuvanted with aluminium hydroxide alone, showed the higher local reaction rate in AS04-adjuvanted vaccine group. It is associated with the most likely related to the use of the immunostimulant in AS04.
Virosomes provide the unique opportunity to combine a vaccine antigen and an adjuvant within a single particle. That can be targeted to define cell populations of the immune system. Theoretically, all vaccines can be developed using virosomal approach/technique, but due to the complexity of manufacturing, virosomes have only been used in Influenza (Inflexal® V) and Hepatitis A (Epaxal®) vaccines. Good safety and immunogenicity of Inflexal® were demonstrated in some studies. A multicentre study of 533 elderly subjects showed that Inflexal® V was better than the comparator using MF59 as an adjuvant in terms of pain, systemic reactions and additional medication to treat vaccine-related AEs. Inflexal® V was found to possess very good immunogenicity for two of the three vaccine strains. The main advantage was found to be in subjects who possessed non-protective antibody levels at baseline. Inflexal® was also found safe and effective in healthy children and HIVpositive children.
Every adjuvant has a complex and often multifactorial immunological mechanism, usually poorly understood in vivo. Figure 3 shows the proposed mechanism of actions of the different adjuvants. Traditionally, adjuvants have been classified as delivery systems and immunopotentiators. The safety profile of an adjuvant, including the actual and hypothetical risks, is a critical factor that can speed up or impede adjuvant development. To date, there are 5 licensed vaccine adjuvants in US and Europe: Aluminium salts (EU, US), MF59 (EU), AS03 (EU), AS04 (EU, US), and Virosomes (EU). All vaccines that contain these adjuvants have been proven safe, with the exception of the AS03, for which the rare events of narcolepsy have been reported in some countries. Adjuvants have been linked to many theoretical risks, but the studies conducted do not support the causal relationship. The benefits of using adjuvanted-vaccines outweigh the risks. Rational development of classical and novel adjuvants will continue to be one of the most important challenges for the vaccinologist to be able to address persistent unmet medical needs.
CONCLUSION
Adjuvants are molecules, compounds or macromolecular complexes that enhance the potency and longevity of specific immune response to antigens. Every adjuvant has a complex and often multifactorial immunological mechanism, usually poorly understood in vivo. Traditionally, adjuvants have been classified as delivery systems and immunopotentiators. The safety profile of an adjuvant, including the actual and hypothetical risks, is a critical factor that can speed up or impede adjuvant development. To date, there are 5 licensed vaccine adjuvants in US and Europe: Aluminium salts (EU, US), MF59 (EU), AS03 (EU), AS04 (EU, US), and Virosomes (EU). All vaccines that contain these adjuvants have been proven safe, with the exception of the AS03, for which the rare events of narcolepsy have been reported in some countries. Adjuvants have been linked to many theoretical risks, but the studies conducted do not support the causal relationship. The benefits of using adjuvanted-vaccines outweigh the risks. The increasing understanding in adjuvant sciences is fundamental to the further development of new adjuvants, which may eventually result the development of safer and more effective vaccines.
